Home / Pharma Healthcare / Global Artificial Pancreas Devices Systems Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Global Artificial Pancreas Devices Systems Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • Id : RNR-264981
  • Category : Pharma Healthcare
  • Publish Date : Mar-2019
  • Publisher : GlobalInfo Research
  • Pages : 119
  • Format : PDF
License Type

The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a 'closed-loop' system, an 'automated insulin delivery' system, or an 'autonomous system for glycemic control.'
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.


The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.

The worldwide market for Artificial Pancreas Devices Systems is expected to grow at a CAGR of roughly 13.8% over the next five years, will reach 120 million US$ in 2024, from 56 million US$ in 2019, according to a new GIR (Global Info Research) study.

This report focuses on the Artificial Pancreas Devices Systems in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Bigfoot Biomedical
Beta Bionics
Tandem Diabetes Care
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Market Segment by Applications, can be divided into